Grand Pharmaceutical's (HKG:0512) experimental cancer diagnostic candidate GPN01530-2 has received fast track designation from the U.S. Food and Drug Administration.
The designation allows for more frequent discussions with the FDA and may support priority and rolling review of a future drug application, the pharma company said in a Hong Kong bourse filing on Sunday. The candidate was previously cleared by the FDA to enter a Phase I/II clinical study for diagnosing solid tumors.
Shares of the company jumped 5% in recent trade.